C5 and atypical hemolytic-uremic syndrome: In humans, Ravulizumab, a monoclonal antibody to complement C5, has been approved for atypical hemolytic uremic syndrome and is being evaluated in early-phase and preclinical studies for reducing renal disorders [63].